| Outcome Measures: |
Primary: Number of Participants Experiencing an Adverse Event (AE), Up to Day 36|Number of Participants Withdrawing From Study Therapy Due to an AE, Up to Day 22 | Secondary: Percent Inhibition of Dipeptidyl Peptidase-4 (DPP-4) After Day 15, Percent DPP-4 inhibition at 168 hours after the Day 15 dose (from baseline \[pre-dose on Day 1\]) was compared in healthy and T2D participants receiving omarigliptin or placebo., 168 hours post-dose on Day 15|Percent Inhibition of DPP-4 After Day 22, Percent DPP-4 inhibition at 168 hours after the Day 22 dose (from baseline \[pre-dose on Day 1\]) was compared in healthy and T2D participants receiving omarigliptin or placebo., 168 hours post dose on Day 22|WAA Active Glucagon-like Peptide-1 (GLP-1) Concentration, Weighted average augmentation (WAA) active GLP-1 concentration was based on the 0.25, 0.5, 1, 2, and 4 hour timepoints. WAA was calculated as area under the curve (AUC) for the 4-hr post-dose time period (AUC0-4 hrs); this AUC was then divided by the time interval of 4 hours to obtain WAA. Log scale data were then back-transformed to obtain LS means., Through 4 hours post dose on Day 21|WAA Total GLP-1 Concentration, WAA total GLP-1 concentration was based on the 0.25, 0.5, 1, 2, and 4 hour timepoints. WAA was calculated as AUC0-4 hrs; this AUC was then divided by the time interval of 4 hours to obtain WAA. Log scale data were then back-transformed to obtain LS means., Through 4 hours post dose on Day 21|Plasma Glucose Concentration, Post-prandial glucose concentration is presented as a weighted average of the 0.25, 0.5, 1, 2, and 4 hour post-dose time points. Glucose concentration was calculated as area under the curve (AUC) for the 4-hr post-dose time period (AUC0-4 hrs); this AUC was then divided by the time interval of 4 hours to obtain weighted average glucose concentration. Log scale data were then back-transformed to obtain LS means., Through 4 hours post dose on Day 21
|
